By creator to www.prnewswire.com
FRAMINGHAM, Mass., March 2, 2021 /PRNewswire/ — Transplant Genomics (“TGI”), the transplant rejection diagnostics firm dedicated to bettering organ transplant outcomes worldwide, publicizes the appointment of Nicholas (Nik) Grund as President. Mr. Grund is accountable for creating and implementing new methods to proceed to develop Transplant Genomics’ present enterprise; increasing the TruGraf portfolio into new organ sorts; and dealing with prospects, advocates, and payers to ascertain long run value-based relationships.
Mr. Grund brings greater than 25 years of business management expertise within the biopharmaceutical trade to TGI, together with a number of world govt roles in finance, gross sales, and advertising and marketing. He joins TGI from AMAG Prescribed drugs, the place he spent three years as Chief Business Officer and achieved double-digit progress by way of new product launches and label expansions. Previous to AMAG, Mr. Grund spent 13 years at Sanofi, most lately because the chief of the corporate’s uncommon illness and a number of sclerosis franchises within the Asia Pacific area and Canada. He holds a Bachelor of Science in Enterprise Administration from the College of Massachusetts and a Grasp of Enterprise Administration from Northeastern College.
Mr. Grund will spearhead firm initiatives to extend TruGraf utilization within the community-based nephrology market, which offers long-term look after >80% of all kidney transplant recipients. He may even shepherd the launch of TruGraf Liver within the latter half of 2021, increasing the advantages of non-invasive TruGraf testing to enhance outcomes in liver transplant recipients.
Along with Mr. Grund, Transplant Genomics welcomes John Slaught as VP Gross sales and Charles (Chuck) Argentine as Director of Medical Operations, rounding out TGI’s management crew to proceed to develop the enterprise in 2021 and past.
Mr. Slaught brings greater than 25 years of business crew management to TGI, with a historical past of constructing and main profitable gross sales and repair enterprises in area of interest therapeutic areas. Mr. Slaught was most lately VP Gross sales with Optum, a UnitedHealth Group firm, the place he led a $4.5 billion Specialty and Dwelling Infusion pharmacy. He holds a Bachelor of Science in Enterprise from the College of San Diego and a Grasp of Enterprise Administration from Pepperdine College.
Mr. Argentine involves TGI with greater than 15 years of laboratory administration expertise, primarily within the areas of genetic sequencing and immunology. He was most lately Director of Medical Laboratory Operations at Roche Sequencing Options, the place his management resulted in vital enhancements within the throughput of high-complexity genetic assays. Mr. Argentine holds a Bachelor of Science in Molecular Biology from the College of California, Davis.
For extra info:
Transplant Genomics, Inc.
e) [email protected]
About Transplant Genomics, Inc.
Transplant Genomics, Inc. (“TGI”) is a customized diagnostics firm dedicated to bettering organ transplant outcomes worldwide by way of progressive checks that detect early indicators of graft damage, differentiate amongst actionable causes, and allow the optimization of remedy. Working alongside the transplant neighborhood and inside the Eurofins household, TGI is commercializing a set of checks enabling diagnoses and prediction of transplant recipient immune standing. Our flagship product is TruGraf, the one non-invasive blood check authorised by CMS that provides the earliest potential detection of “silent” subclinical acute rejection in kidney transplant recipients with steady graft operate. Take a look at providers are supplied by way of TGI’s CLIA laboratory in Fremont, CA. TGI was acquired by Eurofins Scientific in 2019.
Be taught extra about Transplant Genomics at http://www.transplantgenomics.com.
About Eurofins Scientific
Eurofins Scientific, by way of its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it’s the world chief in meals, environmental, pharmaceutical and cosmetics merchandise testing and in agroscience CRO providers. It’s also one of many world impartial market leaders in sure testing and laboratory providers for genomics, discovery pharmacology, forensics, CDMO, superior materials sciences and within the assist of scientific research. As well as, Eurofins is without doubt one of the main world rising gamers in esoteric and molecular scientific diagnostic testing. With over 50,000 employees throughout a community of greater than 900 impartial corporations in over 50 international locations usually specialised by finish consumer markets and working greater than 800 laboratories, Eurofins presents a portfolio of over 200,000 analytical strategies to judge the protection, identification, composition, authenticity, origin, traceability and purity of a variety of merchandise, in addition to offering progressive scientific diagnostic testing providers. The Group’s goal is to supply its prospects with high-quality and progressive providers, correct outcomes on time and, when requested, professional recommendation by its highly-qualified employees.
Eurofins is dedicated to pursuing its dynamic progress technique by increasing each its expertise portfolio and its geographic attain. By way of R&D and acquisitions, the Group attracts on the newest developments within the discipline of biotechnology and analytical chemistry to supply its shoppers distinctive analytical options and a really giant vary of testing strategies.
As some of the progressive and quality-oriented worldwide teams in its trade, Eurofins is ideally positioned to assist its shoppers’ more and more stringent high quality and security requirements and the rising calls for of regulatory authorities and healthcare practitioners all over the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Inventory Change (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Be taught extra about Eurofins at https://www.eurofins.com.
SOURCE Transplant Genomics, Inc.
— to www.prnewswire.com